Clinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares

Stock News

Mar 10

Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The gains followed news that on March 9, the CDE website indicated that the SKB575 (HBM7575) injection, jointly submitted by SKB BIO-B and HBM HOLDINGS-B, had received clinical trial approval for the treatment of atopic dermatitis. This marks the first bispecific antibody from the partners’ autoimmune disease collaboration pipeline to enter the clinical stage. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, featuring a dual mechanism of action. On one hand, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the other undisclosed target is expected to produce a synergistic effect, overcoming resistance issues associated with single-target TSLP antibodies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1148853674"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148853674\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148853674?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 10:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148853674","market":"other","top_or_hot":-1,"title":"Clinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares","media":"Stock News","content":"<p>Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The gains followed news that on March 9, the CDE website indicated that the SKB575 (HBM7575) injection, jointly submitted by SKB BIO-B and HBM HOLDINGS-B, had received clinical trial approval for the treatment of atopic dermatitis. This marks the first bispecific antibody from the partners’ autoimmune disease collaboration pipeline to enter the clinical stage. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, featuring a dual mechanism of action. On one hand, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the other undisclosed target is expected to produce a synergistic effect, overcoming resistance issues associated with single-target TSLP antibodies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-10 10:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The gains followed news that on March 9, the CDE website indicated that the SKB575 (HBM7575) injection, jointly submitted by SKB BIO-B and HBM HOLDINGS-B, had received clinical trial approval for the treatment of atopic dermatitis. This marks the first bispecific antibody from the partners’ autoimmune disease collaboration pipeline to enter the clinical stage. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, featuring a dual mechanism of action. On one hand, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the other undisclosed target is expected to produce a synergistic effect, overcoming resistance issues associated with single-target TSLP antibodies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0196878994.USD","symbol_name":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","start_time":0,"source_url":"","article_id":"1148853674","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148853674","pubTimestamp":1773109105,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","02142":"和铂医药-B","06990":"科伦博泰生物-B","BK1583":"高瓴概念","BK1161":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard"},"translate_title":"TSLP双特异性抗体临床试验获批提振SKB BIO-B和HBM HOLDINGS-B股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"06990":1,"02142":1},"content_text":"Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The gains followed news that on March 9, the CDE website indicated that the SKB575 (HBM7575) injection, jointly submitted by SKB BIO-B and HBM HOLDINGS-B, had received clinical trial approval for the treatment of atopic dermatitis. This marks the first bispecific antibody from the partners’ autoimmune disease collaboration pipeline to enter the clinical stage. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, featuring a dual mechanism of action. On one hand, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the other undisclosed target is expected to produce a synergistic effect, overcoming resistance issues associated with single-target TSLP antibodies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}